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Abstract
Background: Prescription narcotic overdoses and abuse have reached alarming numbers. To address this epidemic,
integrated clinical decision support within the electronic medical record (EMR) to impact prescribing behavior was
developed and tested.
Methods: A multidisciplinary Expert Panel identified risk factors for misuse, abuse, or diversion of opioids or
benzodiazepines through literature reviews and consensus building for inclusion in a rule within the EMR. We ran
the rule “silently” to test the rule and collect baseline data.
Results: Five criteria were programmed to trigger the alert; based on data collected during a “silent” phase, thresholds
for triggers were modified. The alert would have fired in 21.75 % of prescribing encounters (1.30 % of all encounters;
n = 9998), suggesting the alert will have a low prescriber burden yet capture a significant number of at-risk patients.
Conclusions: While the use of the EMR to provide clinical decision support is not new, utilizing it to develop and test
an intervention is novel. We successfully built an alert system to address narcotic prescribing by providing critical,
objective information at the point of care. The silent phase data were useful to appropriately tune the alert and obtain
support for widespread implementation. Future healthcare initiatives can utilize similar methodology to collect data
prospectively via the electronic medical record to inform the development, delivery, and evaluation of interventions.
Keywords: Opioids, Electronic medical record, Prescription drug abuse, Clinical decision support
Abbreviations: EMR, electronic medical record; PDMP, prescription drug monitoring program; PRIMUM, Prescription
Reporting with Immediate Medication Utilization Mapping
Background
Increases in opioid prescriptions for acute and chronic
pain have led to rises in abuse and overdose of prescrip-
tion narcotics [1]. Unintentional poisonings due to opi-
oid abuse and misuse is an ever growing and significant
cause of death and injury. While opioids are the most
common class of scheduled medications involved in
deaths related to pharmaceutical overdose (75.2 %), ben-
zodiazepines are involved in nearly a third of these
overdoses (29.4 %). Additionally, the combination of opi-
oids and benzodiazepines is especially dangerous, with
opioids implicated in 77.2 % of deaths involving benzo-
diazepines, making these two classes of drugs the target
of many interventions [2]. Nearly 15,000 people in the
United States die from prescription painkiller overdoses
every year [3]. In the past 12 years, the rates of uninten-
tional poisoning deaths have surpassed motor vehicle
deaths in many states; specifically, unintentional poison-
ing deaths in North Carolina have risen 308 % [4, 5].
All levels of government in the United States recognize
the crisis of prescription narcotics. The Executive Office
of the President recently released a National Plan for
Prescription Drug Abuse, detailing goals relative to this
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problem, including encouraging and even rewarding pre-
scribers who check Prescription Drug Monitoring Pro-
grams (PDMP) before writing prescriptions for opioids.
The document went further with a call to find ways to
utilize the electronic medical record (EMR) to help iden-
tify and curb prescription drug abuse [6]. In fact, the
2016 budget includes $133 million in new funding to ad-
dress opioid misuse and abuse, leading the U.S. Health
and Human Services Secretary to announce an initiative
focusing on three priority areas—prescriber guidelines,
naloxone, and medication-assisted treatment—to address
the issue [7]. The Centers for Disease Control and Pre-
vention also recognizes the importance of improving
opioid prescribing practices as a strategy to reduce the
number of people who misuse, abuse, or overdose from
these medications [3].
Opioids and benzodiazepines are considered con-
trolled substances according to the U.S. Drug Enforce-
ment Administration, based on the potential for abuse
or dependency [8]. Prescribers in the outpatient setting
(primary care, internal medicine, and dentists) generate
the majority of prescriptions for these controlled sub-
stances [9]. In fact, several sources suggest that a small
number of these prescribers generate the vast majority
of controlled substance prescriptions [10–12]. Therefore,
interventions targeting prescribing behavior holds con-
siderable potential for addressing this epidemic. “First do
no harm”, or Primum non nocere, is a guiding principle
in medicine. PRIMUM provides prescribers with critical
information to put this principle into practice.
Frequently, prescribers in different care settings are
blind to patient interaction with prescribers in other fa-
cilities or the critical information that is buried within
the overwhelming amount of health information in each
patient’s electronic record [13, 14]. Multiple attempts to
utilize the EMR and institute computerized physician
order entry (CPOE) and computer-based clinical decision
support have proven successful. Current alert systems pro-
grammed into the EMR are designed to make the pre-
scriber aware of critical information. Health maintenance
reminders, allergy alerts, prescription drug interaction
alerts, and systems to alert physicians to contraindications
due to chronic condition or medications are all imbedded
in healthcare systems and physician practices [15–19].
Some of these alerts have resulted in behavior change
through increased vaccination rates [20], increased use of
prophylaxis among patients at risk for deep-vein throm-
bosis and pulmonary embolism [21], and reduction of pre-
scriptions for contraindicated agents [17], among others.
However, the number of alerts have grown to the point
where physicians may see 80 alerts per 100 medications or-
dered, causing these alerts to be ignored in up to 90 % of
cases [22], so it is important to spend a significant amount
of time developing and testing an alert to maximize its’
clinical utility. Research on alert systems indicates that sys-
tems focusing on critical information that is clear, concise,
and timely is most likely to be well-received and have a
positive impact [23–25]. Alert triggers must be optimized
to focus on the specific population of interest because
alerts that interrupt work flow too often introduce “alert
fatigue” and will be ignored [24, 26].
We propose using a technological solution – clinical
decision support logic built into the EMR—to help ad-
dress the problem of unintentional poisonings. Clinical
decision support has been developed to increase adher-
ence to clinical practice guidelines for opioid therapy for
chronic non-cancer pain in the primary care setting, in-
cluding dosing recommendations and contraindications
[27, 28]. However, EMR-integrated alert systems have not
previously been used to identify patients with evidence-
based risk factors for misuse, abuse, or diversion of pre-
scription narcotics, including both opioids and benzodiaz-
epines. Additionally, we believe this is the first attempt to
provide decision support in the acute setting.
A multidisciplinary team within our large healthcare
system sought to address the prescription narcotic epi-
demic. The “Prescription Reporting and Immediate Medi-
cation Utilization Mapping” intervention, or PRIMUM, is
the result of these efforts. We saw an opportunity to utilize
the EMR to map prescription utilization and to provide
real-time information to prescribers at the point of care,
analyze the data on a continuous basis, and make improve-
ments to the system based on feedback from physicians
and other prescribers in our numerous care locations,
encompassing outpatient clinics, emergency departments,
urgent care centers, and hospitals.
The purpose of our investigation was:
1. To create a rule within the EMR to identify at risk
patients utilizing searchable, objective indicators of
risk for misuse, abuse, and diversion of prescription
controlled substances based on peer-reviewed
literature and consensus opinion.
2. To use data generated by the rule in an iterative
improvement process to tune the timing of the
alert and thresholds for the triggers to produce
an acceptable number of relevant alerts at the
point of care.
Methods
A multidisciplinary team developed and implemented an
alert system that provides integrated clinical decision
support into the electronic medical record to impact
prescribing behavior and, thereby, reduce prescriptions
for opioids and benzodiazepines for at-risk patients to
ultimately impact patient outcomes. The development
and testing of the rule occurred between December 2014
and May 2015, within our large, integrated healthcare
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system with a common EMR. A list of terms and defini-
tions related to this alert system is provided in Table 1.
Context
Our healthcare system presents a unique opportunity to
test this innovative intervention, with over 40 hospitals,
6 freestanding emergency departments, 28 urgent care
locations, and ~800 physician practices with over 15,000
physicians. A common EMR, Cerner [29], is used by a
subset of these facilities, and participated in the imple-
mentation of PRIMUM. 15 hospitals, 6 freestanding
emergency departments, 27 urgent care locations, and
379 physician practices with over 2500 prescribers were
included in the PRIMUM implementation and evalu-
ation. The PRIMUM rule was written into the Cerner
EMR using a standard rule template included as part of
the EMR program. All of the sites utilizing Cerner were
included in all phases of the implementation and testing.
Aim 1
To create a rule within the EMR to identify at risk pa-
tients utilizing searchable, objective indicators of risk for
misuse, abuse, and diversion of prescription controlled
substances based on peer-reviewed literature and con-
sensus opinion.
Identification of the risk factors
An Expert Panel of study co-investigators and other key
stakeholders, including clinical and research faculty from
multiple surgical and medical specialties (Emergency
Medicine, Behavioral Health, Orthopaedic Surgery, In-
ternal Medicine, Pharmacy), senior healthcare system
physician and administration leadership, Information Ser-
vices, and experts in the field of unintentional poisoning
was convened. Considerable effort was placed on ensuring
engagement from physicians, researchers, and all levels of
healthcare system administration, including presentations
to system-level committees, individual meetings, and
grand rounds lectures for physicians across the system.
The Expert Panel was charged with selecting criteria that
would indicate risk of misuse, abuse, or diversion of pre-
scription narcotics for potential inclusion in a rule built
within the EMR. Review of current medical literature was
utilized to identify evidence for or against inclusion of
these perceived risk factors.
Further extensive literature review conducted by the
Expert Panel generated a more expansive list of risk fac-
tors associated with misuse, abuse, or diversion of pre-
scription drugs, including demographic characteristics,
medical conditions, prescription history and details, and
a variety of identified high risk behaviors. A complete
listing of all risk factors identified in the peer-reviewed
literature is presented in Table 2. Following the system-
atic review of the literature to outline all potential risk
factor, the team worked collaboratively to determine the
risk factors to be built into the rule.
Selecting the triggers
To develop an alert based on these risk factors in the
EMR, the criteria must be consistently and accurately
documented in the EMR in a specific location that can
be searched in an automated fashion. In addition, inves-
tigators agreed to focus on objective risk characteristics
rather than on subjective or anecdotal assessments of
patient risk or behavior in order to limit the potential
for the rule introducing bias into the medical encounter.
The risk factors were mapped against objective data
available and searchable in the EMR to determine which
risk factors were initially eligible for inclusion. Demo-
graphic characteristics and many comorbidities were ex-
cluded as potential triggers as they may indicate risk but
have low specificity and, while associated, are not on the
causal pathway. Given that many of the documented drug-
seeking behaviors are more subjective and are not immedi-
ately searchable in the EMR, they were not included as
triggers. The remaining indicators of risk included pre-
scription details, administration of controlled substances,
and information about substance use.
Expert panel discussions of these remaining risk fac-
tors yielded 5 categories of objective information avail-
able in the EMR that speaks to risk for misuse, abuse, or
diversion and that were agreed upon by all members of
the panel: current open prescriptions [30–32]; visits to
emergency departments or urgent care facilities with
onsite treatment with narcotics; 30 day prescription nar-
cotic history [33–35]; history of overdose [36]; and his-
tory of positive drug or alcohol screens within the EMR
[36–39]. The expert panel came to a consensus on the
initial threshold for each trigger based on the literature
as well as clinical experience in a variety of specialties
with diverse patient populations.
Table 1 Definitions
Rule The rule is executed every time a prescription for an opioid
or benzodiazepine is initiated. The rule is programmed to
search the medical record for the triggers.
Trigger Triggers are the criteria the rule searches for in the medical
record. These triggers are indicators of risk for opioid or
benzodiazepine misuse, abuse, and/or diversion.
Alert The alert is the pop-up box that appears when the rule
identifies the patient to meet one or more of the trigger
criteria. The alert interrupts workflow and requires the
prescriber to either override the alert and continue with the
prescription or cancel the prescription before proceeding.
Patient
Encounters
A patient encounter is any medical visit or interaction a
patient has with a system provider. This includes inpatient
stays, outpatient visits, lab visits, and ED/Urgent Care visits.
Prescribing
Encounters
Any patient encounter in which a prescriber initiates a
prescription for one or more opioids or benzodiazepines
is defined as a prescribing encounter.
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Aim 2
To use data generated by the rule in an iterative im-
provement process to tune the timing of the alert and
thresholds for the triggers to produce an acceptable
number of relevant alerts at the point of care.
“Silent” data collection
We used the EMR rule to prospectively collect surveil-
lance data on narcotic prescriptions (defined as opioids
or benzodiazepines) within our health system in a series
of defined silent periods. This rule would eventually
power the alert in the EMR; however, we were able to
run it “silently” (no alert displayed to prescribers) in
order to collect data needed to create an effective alert.
During the silent phase, the rule captured information
about each patient encounter in which an opioid or
benzodiazepine was prescribed, including the selected
triggers, patient identifiers, location, encounter type, pre-
scriber information, and the medication prescribed.
The first data collection period, Silent Surveillance 1,
lasted 1 month and focused on testing the programming
of the rule and report generation. We also reviewed pre-
liminary data on risk characteristics and the rate at
which the alert would have been triggered. Silent Sur-
veillance 2 was conducted for 1 month to ensure the risk
criteria were appropriately tuned and to describe the
narcotics prescribing patterns across the system.
Tuning the trigger thresholds
These triggers were included in a rule developed to re-
trieve these data from the EMR in real-time and present
them to the prescriber at the point of care. In order to
assure appropriate tuning of the triggers, we used Silent
Surveillance 1 data to revise the triggers to optimize sen-
sitivity and provide meaningful and actionable informa-
tion to prescribers while minimizing prescriber burden
and alert noise [40]. We did not set an a priori alert rate
for the triggers. Rather, the panel reviewed the patient
populations being captured and missed by the current
thresholds and came to a consensus to revise thresholds
accordingly. These revised trigger thresholds were moni-
tored during Silent Surveillance 2.
Tuning the timing
The timing of the alert presentation to the prescriber is
critical. The information needs to be presented early
enough in the encounter to affect prescribing behavior
for the at-risk patients. However, if the alert appears too
early in the encounter, it could bias the entire patient
visit. Some data suggest that the patient-clinician rela-
tionship can affect patient outcome [41], so unnecessary
bias of this relationship could cause harm. If the alert
appears later in the encounter, after the full prescription
has been written, it would improve data capture for the
purpose of research, but may contribute to work flow
Table 2 Risk Factors Associated with Misuse, Abuse, or Diversion of Prescription Drugs
Demographic characteristics Medical conditions Prescription details High risk behaviors




High school education or less
[49, 53, 54]
Age (Younger to middle aged)
[34, 37, 53, 55, 56]
Not married [37, 50, 53, 54]
Financial Problems [37]
Unemployed [37]
Male [34, 35, 53, 55, 57]
Income extremes [34, 53, 55, 57]
Rural residence [34, 37]
LGBT [57]
Public insurance [55]
Low social class [58]
Family history of substance
abuse [59]
Preadolescent sexual abuse [59]
Past Suicide Attempt [49]
Lifetime Heroin use [49]
Pain [39, 49, 50, 54, 60–62]
Tobacco use [37, 54]
Alcohol use [37–39, 57, 59]
Current illicit drug use
(including marijuana, cocaine,
heroin, methamphetamine,
hallucinogens) [37, 39, 57]
Physical disability [37]
Mental health problems
[34, 39, 50, 59, 61, 63]
Substance abuse disorder
[39, 50, 53, 59]




Congestive heart failure [50]
Cerebrovascular disease [50]






Medical comorbidities [55, 63]
Past care at psychiatric hospital [58]
ADHD [64]
Multiple prescribers
[30, 33, 34, 52, 53, 56, 59, 65]
Multiple pharmacies [30, 31, 33, 34, 56]
High community prescribing rates [34]
Treatment with high daily dose
opioids and short-acting opioids [39, 50]
Multiple prescriptions [31, 35, 50, 52, 56]
Overlapping prescriptions [31]
High maximum prescribed daily morphine
equivalent dose [34, 35, 50, 66, 67]
Preexisting opioid use [62]
Co-prescribing of opioids and
benzodiazepines [34]
Multiple prescribers
[30, 33, 34, 52, 53, 56, 59, 65]
Multiple pharmacies [30, 33, 34, 56]
Multiple ED visits [50, 55, 59]
Request for refill [59, 60]
Lost or stolen medication [59, 60]
Request for parenteral medication [60]
Reported allergies to non-narcotic
medications [52]
Requesting medication by name [52]
Weekend visit [52]
Use of alias [68]
Abnormal urine/blood screen [59]
Resist therapy changes/alternative
therapy [59]
Canceled clinic visits [59]
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disruption within a busy practice or even ignoring the
alert since it is after the “point of decision”.
In order to determine the appropriate timing of the
alert, we conducted literature reviews, expert panel discus-
sions, and individual interviews with practicing clinicians
from across the system to obtain feedback. The individual
interviews solicited input from clinicians of varying
experience (resident and attending), various specialties
(emergency medicine, primary care, surgical subspe-
cialties, etc.) and clinician type (physician and nurse
practitioner).
Results
Development of the alert
The following alert triggers were initially programmed
into the rule through the literature search and the expert
panel discussions:
◦ Current prescription with >30 % remaining expected/
early refill (e.g. A prescription written for 10 days
duration was prescribed at least 3 days ago).
◦ 3+ visits to ED or Urgent Care with onsite treatment
with opioids (not including visits leading to
admission) within previous 30 days.
◦ 3+ prescriptions for opioids or benzodiazepines
within previous 30 days.
◦ Previous presentation for overdose within the EMR.
◦ Positive screen for blood alcohol, cocaine, or
marijuana within the EMR.
If one or more of the alert triggers are met, once live,
an alert fires in the EMR and presents the information
to the prescriber (Fig. 1). The alert is concise, clear, and
shows details regarding only the triggers that are applic-
able to that patient [40]. Navigating the alert requires
minimal time; the prescriber choses to continue with the
prescription as planned or to cancel the prescription.
Tuning the timing and trigger thresholds
Peer-reviewed literature, consensus panel and individual
clinician interviews arrived at placing the alert at the
point when the prescriber chooses an opioid or benzodi-
azepine. This timing was chosen to provide the informa-
tion as soon as possible and decrease interruption to
workflow that would occur if the prescriber received the
alert after completing the prescription entirely (i.e. after
completing dosage and pill count information or signing
the prescription). However, the alert does not appear as
soon as the patient record is opened, to avoid labeling pa-
tients in encounters where narcotics or benzodiazepines
are not involved. The feedback from the expert panel and
the clinician interviews was consistent with timing from
human factors research on the electronic medical record
and avoidance of a negative bias on the encounter [42–45].
After reviewing Silent Surveillance 1 data, the thresholds
of two of the triggers were modified (indicated in bold).
The initial “current prescription with >30 % remaining/
early refill” trigger was present in approximately 17 % of
prescriptions. Upon further review of the patients meeting
Fig. 1 Prescription Narcotic Alert in the EMR
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this criteria, many of the early refills were found to be in
primary care offices. Many patients obtain prescriptions
for refills when at a regularly scheduled appointment with
their physician and, therefore, the initial threshold of 30 %
was believed to be too low to appropriately capture the at
risk patient. Conversely, the initial “3+ visits to ED or Ur-
gent Care with onsite treatment” trigger was present in
only 1.58 % of prescriptions. We determined this rate was
low, and we had the potential to identify a greater number
of at risk patients without burdening prescribers with high
alert rates. The Final Triggers programmed into the rule
were:
◦ Current prescription with >50 % remaining expected/
early refill.
◦ 2+ visits to ED or Urgent Care with onsite treatment
with opioids (not including visits leading to
admission) within previous 30 days.
◦ 3+ prescriptions for opioids or benzodiazepines
within previous 30 days.
◦ Previous presentation for overdose within the EMR.
◦ Positive screen for blood alcohol, cocaine, or
marijuana within the EMR.
After revision of the trigger thresholds, Silent Surveil-
lance 2 was conducted, and the rates of alerts and triggers
were reviewed (Table 3). By changing the threshold to
current prescription with >50 % remaining, the rate of this
trigger decreased from 17 % in Silent Surveillance 1 to
13.54 % in Silent Surveillance 2. Decreasing the onsite
treatment with narcotics to 2+ visits in the previous
30 days yielded a rate of 1.96 % instead of 1.58 %. Al-
though this change did not increase the rate drastically,
the modified alert trigger allowed us to identify over 200
additional patients at risk. These new trigger thresholds
were considered appropriately tuned to both identify at
risk patients and balance concerns about alert fatigue
among prescribers. There were a total of 81,841 pre-
scriptions written during this month in 61,747 prescrib-
ing encounters.
The rates of alerts system-wide and by facility type
(inpatient, ED/Urgent Care, and outpatient) are presented
in Fig. 2. A total of 9998 alerts would have been generated
during the month of data collection if the alert were not
in “silent” phase. Overall, once live, the alert would have
fired in 5.97 % of encounters where a prescription for an
opioid or benzodiazepine was written and in only 1.30 %
of all face-to-face patient encounters. Alerts would have
fired most frequently at inpatient discharges (8.53 % of
total discharges) and least frequently in the outpatient set-
ting (0.93 % of patient encounters). These rates indicate
the alert will have a low burden on prescribers, yet suggest
that they will capture a significant number of at-risk pa-
tients, yielding substantial public health impact.
Prescription utilization mapping
The characteristics of prescribing encounters from Silent
Surveillance 2 are presented in Table 3. The volume of
prescriptions varies by location, with the majority of pre-
scribing encounters occurring in outpatient facilities
(62 %). However, the distribution of prescribing encoun-
ters among facility types does not match the distribution
of overall patient encounters. As expected, inpatient dis-
charges and ED/Urgent Care encounters have dispropor-
tionately higher rates of opioid and benzodiazepine
prescriptions compared to the number of patient encoun-
ters. While inpatient discharges make up less than 2 % of
encounters, they represent 7.5 % of prescribing encounters.
Similarly, ED/Urgent Care encounters represent less than
Table 3 Characteristics of Controlled Substance Prescribing
Encounters, Silent Surveillance 2 (n = 61,747 prescribing
encounters)
Characteristic No. (% Prescribing encounters)
Age of patient
< 18 1552 (2.51 %)
18-64 45,571 (73.80 %)
65 14,624 (23.68 %)
Facility type
ED/Urgent Care 18,267 (29.58 %)
Inpatient Discharge 4656 (7.54 %)
Outpatient including phone calls 38,310 (62.04 %)
Other 514 (0.83 %)
Class of drug
Opiate 45,165 (73.15 %)
Benzodiazepine 14,268 (23.11 %)
Both 2314 (3.75 %)
Number of criteria met (of any combination)
0 48,164 (78.00 %)
1 10,517 (17.03 %)
2 2654 (4.30 %)
3 369 (0.60 %)
4 43 (0.07 %)
5 0 (0.00 %)
Criteria met
Prescription with >50 % remaining 8358 (13.54 %)
2+ visits with onsite administration 1208 (1.96 %)
3+ prescriptions in past 30 days 2873 (4.65 %)
Positive tox screen 4165 (6.75 %)
BAC 1444 (2.34 %)
Cocaine 1248 (2.02 %)
Marijuana 2440 (3.95 %)
Previous presentation for overdose 500 (0.81 %)
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10 % of total encounters, yet 29.6 % of prescribing encoun-
ters. While the majority of opioid and benzodiazepine
prescriptions are written to patients 18–64 (73.80 %),
23.7 % are written to older adults (≥65 years of age),
and 2.5 % to children (≤17 years of age). Opiates are
prescribed more frequently (73.2 %) than benzodiazepines,
and 3.8 % of encounters resulted in co-prescribing opiates
and benzodiazepines.
The most common trigger is a current prescription
with >50 % remaining, present in 13.54 % of prescribing
encounters, while previous presentation for overdose is
the least prevalent (0.81 %). The alert would have fired
in 22.00 % of prescribing encounters. While the majority
of patients did not meet any criteria (78.00 %), 4.97 %
of prescribing encounters were with patients meeting
multiple risk criteria.
Fig. 2 Rate of Narcotic/Benzodiazepine Prescription Encounters and Rate of PRIMUM Alert *Note: Due to lack of documentation of phone call
encounters and, therefore, inability to generate an accurate total denominator for patient phone calls requesting prescriptions, these data were
separated in this figure
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Discussion
Prescription opioid and benzodiazepine use has reached
epidemic proportions in the United States. Through
literature review and consensus building with a multi-
disciplinary team, we identified five objective criteria
(See Final Triggers) that indicate high risk for misuse,
abuse, and diversion of prescription opioids and benzodi-
azepines and built an alert system in the electronic med-
ical record of a large healthcare system. We found that a
significant number of patients meeting these criteria are
being prescribed opioids or benzodiazepines, indicating
risk for misuse, abuse, and diversion. However, the alert
will fire in a small percentage of patient encounters, and
thus should not be intrusive to prescribers’ workflow.
We are not aware of any previous studies that have
used this process to prospectively develop and test inter-
ventions in the EMR. However, there are examples in
the literature of utilizing an intensive process of model-
ing clinical data “warehouses” for refining alerts related
to medication orders [46, 47]. These previous authors
utilized clinical data to model outcomes resulting from
various thresholds set for medication alerts. The method
we present in this paper is a novel, and another, ap-
proach to the development, testing, and implementation
of clinical decision support in the EMR. The combin-
ation of expert panel and literature review coupled with
“silent” phases to properly test and tune the triggers
using “live” data is a novel approach that can be utilized
in the development of future EMR-based interventions.
These two “silent” alert phases were extremely useful,
both for obtaining baseline data and to test the alert
prior to launching this intervention. Similar testing of
real clinical data in a non-clinical test environment has
been utilized in other electronic medical record settings
[48]. The data collected allowed us to choose triggers
that did not cause the alert to fire too often, but suc-
cessfully captured the at-risk population. This was im-
portant to minimize the potential for alert fatigue.
These data were also helpful in obtaining support for
deployment of this intervention within the healthcare
system by being able to illustrate the problem, as well
as provide evidence that the alert would be minimally
obtrusive.
This intervention is currently being implemented in
a single, although very large, healthcare system, which
limits the available information about prescriptions or
past medical history to encounters inside this system.
Therefore, future interventions will aim to link to the
state-wide prescription drug monitoring program to ob-
tain a complete prescription history for each patient, as
well as expand to other regional healthcare systems. In
addition, we acknowledge that alerts do not exist in a
vacuum and, while PRIMUM may not be that intrusive to
prescribers, we are unable to determine the number of
alerts a given prescriber might see for a given patient out-
side of the alert for PRIMUM, or the number of alerts
seen during a day or clinical shift. Collaboration and co-
ordination within a large healthcare system to address
clinical decision support is needed. Future research will
analyze the prescriber behavior related to the alert as well
as the appropriateness of these triggers for subpopula-
tions, such as cancer, chronic pain, or palliative care pa-
tients. The data on specific populations will also be used
to develop targeted interventions to assist prescribers and
patients once risk is identified.
Conclusions
Future initiatives in healthcare systems should utilize the
capacity of their EMR to collect data prospectively to in-
form interventions. Given the complexity of a large
healthcare system, it is important that EMR alerts are
tested and tuned sufficiently to ensure a smooth rollout
and that buy-in and support from all stakeholders is ob-
tained early in the process. The utilization of the silent
phases was a useful step that is translatable to other
EMR systems.
Acknowledgments
PRIMUM Group (in alphabetical order): Michael Beuhler, MD; Rebecca Boland;
Michael J. Bosse, MD; Stephen Colucciello, MD; Emily Gerkin; Michael Gibbs,
MD; Christopher Griggs, MD; Anthony Jacobson; Steven Jarrett, PharmD;
Jan Losby, PhD; Monica Mowry, MSN; Michael Runyon, MD; Animita
Saha, MD; Sharon Schiro, PhD; Bradley Watling, MD; Claire Wedgworth;
Stephen Wyatt, DO.
Funding
Financial Support: This work was supported in part by a cooperative
agreement (CE14-004 Award Number CE002520) from the Centers for
Disease Control and Prevention and by an internal grant from the Carolinas
Trauma Network Research Center of Excellence. Disclaimer: The findings and
conclusions in this report are those of the authors and do not necessarily
represent the official position of the Centers for Disease Control and
Prevention (CDC).
Availability of data and materials
Data will not be shared at this time because it contains protected health
information and we are currently analyzing the effectiveness of the alert.
Authors’ contributions
RBS and JRH are the co-principal investigators of this study. RBS, DL, MKW,
JRH, MB, MJB, SC, MG, CG, SJ, MM, MR, AS, BW, and SW contributed to the
conception of the study. RBS, DL, JRH, MB, MJB, SC, MG, CG, SJ, MM, MR, AS,
BW, SW, RB, AJ, and CW contributed to the development of the intervention.
EG, SS, MKW, RBS, and JRH completed the statistical analyses. All authors
contributed to the writing of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This work was conducted following Carolinas HealthCare System Institutional
Review Board review and approval (IRB #12-14-04E) granted on 12/3/2014.
The IRB waived the requirement for obtaining informed consent.
Seymour et al. BMC Medical Informatics and Decision Making  (2016) 16:111 Page 8 of 10
Received: 3 March 2016 Accepted: 18 August 2016
References
1. Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital signs: Overdoses of
prescription opioid pain relievers–United States, 1999–2008. MMWR. 2011;
60(43):1487–92.
2. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United
States, 2010. JAMA. 2013;309(7):657–9. doi:10.1001/jama.2013.272.
3. Centers for Disease Control and Prevention. Vital signs: overdoses of
prescription opioid pain relievers–United States, 1999-2008. MMWR. 2011;60:
1487-92.
4. Bronson WD. The North Carolina Controlled Substances Reporting
System: A valuable tool for combating prescription drug misuse. NCMJ.
2013;74(3):249–53.
5. Ford MD. Unintentional poisoning in North Carolina: An emerging public
health problem. NCMJ. 2010;71(6):542–6.
6. Executive Office of the President of the United States. Epidemic:
Responding to America’s Prescription Drug Abuse Crisis 2011. Available
at https://www.whitehouse.gov/sites/default/files/ondcp/policy-and-
research/rx_abuse_plan.pdf. Accessed June 2015.
7. US Department of Health and Human Services. HHS takes strong steps to




8. US Drug Enforcement Administration. Drug Scheduling. 2016. http://www.
dea.gov/druginfo/ds.shtml. Accessed Feb 2016.
9. Volkow ND, Mclellan TA, Cotto JH. Characteristics of opioid prescriptions in
2009. JAMA. 2011;305(13):1299–300. doi:10.1001/jama.2011.401.
10. Blumenschein K, Fink JL, Freeman PR, Kirsh KL, Steinke DT, Talbert J.
Independent evaluation of the impact and effectiveness of the Kentucky All
Schedule Prescription Electronic Reporting System (KASPER): Institute for
Phamaceutical Outcomes and Policy 2010. Available at http://www.chfs.ky.
gov/NR/rdonlyres/24493B2E-B1A1-4399-89AD-1625953BAD43/0/
KASPEREvaluationFinalReport10152010.pdf. Accessed June 2015.
11. Dhalla IA, Mamdani MM, Gomes T, Juurlink DN. Clustering of opioid
prescribing and opioid-related mortality among family physicians in Ontario.
Can Fam Physician. 2011;57(3):e92–6.
12. Swedlow A, Ireland J, Johnson G. Prescribing patterns of schedule II opioids
in California workers’ compensation: California Workers’ Compensation
Institute 2011. Available at www.cwci.org/document.php?file=1438.pdf.
Accessed June 2015.
13. Singh H, Spitzmueller C, Petersen NJ, Sawhney MK, Sittig DF. Information
overload and missed test results in electronic health record-based settings.
JAMA Internal Med. 2013;173(8):702–3. doi:10.1001/2013.jamainternmed.61.
14. Holden RJ. Cognitive performance-altering effects of electronic medical
records: an application of the human factors paradigm for patient safety.
Cogn Tech Work. 2011;13:11–29.
15. Hunt DL, Haynes B, Hanna SE, Smith K. Effects of computer-based clinical
decision support systems on physician performance and patient outcomes: A
systematic review. JAMA. 1998;280(15):1339–46. doi:10.1001/jama.280.15.1339.
16. Shea S, Dumouchel W, Bahamonde L. A meta-analysis of 16 randomized
controlled trials to evaluate computer-based clinical reminder systems
for preventive care in the ambulatory setting. J Am Med Inform Assoc.
1996;3(6):339–409.
17. Smith DH, Perrin N, Feldstein A, Yang X, Kuang D, Simon SR, et al. The
impact of prescribing safety alerts for elderly persons in an electronic
medical record: An interrupted time series evaluation. Arch Intern Med.
2006;166:1098–104. doi:10.1001/archinte.166.10.1098.
18. Pearson SA, Moxey A, Robertson J, Hains I, Williamson M, Reeve J, et al.
Do computerised clinical decision support systems for prescribing change
practice? A systematic review of the literature (1990–2007). BMC Health Serv
Res. 2009;9:154. doi:10.1186/1472-6963-9-154.
19. McCoy AB, Thomas EJ, Krousel-Wood M, Sittig DF. Clinical decision support
alert appropriateness: A review and proposal for improvement. Ochsner J.
2014;14:195–202.
20. Loo TS, Davis RB, Lipsitz LA, Irish J, Bates CK, Agarwal K, et al. Electronic
medical record reminders and panel management to improve
primary care of elderly patients. Arch Intern Med. 2011;171(17):1552–8.
doi:10.1001/archinternmed.2011.394.
21. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, et al.
Electronic alerts to prevent venous thromboembolism among hospitalized
patients. N Engl J Med. 2005;352(10):969–77. doi:10.1056/NEJMoa041533.
22. Perna G. Clinical alerts that cried wolf. As clinical alerts pose physician
workflow problems, healthcare IT leaders look for answers. Healthc Inform.
2012;29(4):18–20.
23. Feldstein AC, Smith DH, Robertson NR, Kovach CA, Soumerai SB, Simon SR,
et al. Decision Support System Design and Implementation for Outpatient
Prescribing: The Safety in Prescribing Study. In: Henriksen K, Battles JB, Marks
ES, editors. Advances in Patient Safety: From Research to Implementation.
Rockville: Agency for Healthcare Research and Quality; 2005. p. 35–50.
24. Shah NR, Seger AC, Seger DL, Fiskio JM, Kuperman GJ, Blumenfeld B, et al.
Improving acceptance of computerized prescribing alerts in ambulatory
care. J Am Med Inform Assoc. 2006;13(1):5–11. doi:10.1197/jamia.M1868.
25. van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in
computerized physician order entry. J Am Med Inform Assoc. 2006;13(2):
138–47. doi:10.1197/jamia.M1809.
26. Ulrich B. Alarm fatigue: A growing problem. Nephrol Nurs J. 2013;40(4):293.
27. Trafton J, Martins S, Michel M, Wang D, Tu S, Clark D, et al. Designing an
automated clinical decision support system to match clinical practice
guidelines for opioid therapy for chronic pain. Implement Sci. 2010;5(26):1–11.
28. Trafton J, Martins S, Michel M, Lewis E, Wang D, Combs A, et al. Evaluation
of the acceptability and usability of a decision support system to encourage
safe and effective use of opioid therapy for chronic, noncancer pain by
primary care providers. Pain Med. 2010;11(4):575–85.
29. Cerner. Company Fact Sheet. 2015. http://www.cerner.com/uploadedFiles/
Content/About_Cerner/Fact%20Sheet_2016Q1.pdf. Accessed June 3 2016.
30. Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN. Effect
of a centralized prescription network on inappropriate prescriptions
for opoid analgesics and benzodiazepines. CMAJ. 2012;184(16):E852–6.
doi:10.1503/cmaj.121495.
31. Yang Z, Wilsey B, Bohm M, Weyrich M, Roy K, Ritley D, et al. Defining
risk of prescription opioid overdose: pharmacy shopping and
overlapping prescriptions among long-term opioid users in medicaid.
J Pain. 2015;16(5):445–53. doi:10.1016/j.jpain.2015.01.475.
32. Mack KA, Zhang K, Paulozzi L, Jones C. Prescription practices involving
opioid analgesics among Americans with Medicaid, 2010. J Health Care
Poor Underserved. 2015;26(1):182–98. doi:10.1353/hpu.2015.0009.
33. Grover CA, Garmel GM. How Do Emergency Physicians Interpret Prescription
Narcotic History When Assessing Patients Presenting to the Emergency
Department with Pain? Perm J. 2012;16(4):32–6. doi:10.7812/TPP/12-038.
34. Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. 2012;43(4):283–9.
doi:10.1016/j.jsr.2012.08.009.
35. Paulozzi LJ, Kilbourne EM, Shah NG, Nolte KB, Desai HA, Landen MG, et al. A
history of being prescribed controlled substances and risk of drug overdose
death. Pain Med. 2012;13:87–95. doi:10.1111/j.1526-4637.2011.0160.x.
36. Colburn JL, Jasinski DR, Rastegar DA. Long-term opioid therapy, aberrant
beaviors, and substance misuse: Comparison of patients treated by resident
and attending physicians in a general medical clinic. J Opioid Manag.
2012;8(3):153–60. doi:10.5005/jom.2012.0111.
37. Johnson EM, Lanier WA, Merrill RM, Crook J, Porucznik CA, Rolfs RT, et al.
Unintentional prescription opioid-related overdose deaths: description of
decedents by next of kin or best contact, Utah, 2008–2009. J Gen Intern
Med. 2012;28(4):522–9. doi:10.1007/s11606-012-2225-z.
38. Jones CM, Paulozzi LJ, Mack KA. Alcohol Involvement in Opioid Pain
Reliever and Benzodiazepine Drug Abuse-Related Emergency
Department Visits and Drug-Related Deaths–United States, 2010.
MMWR. 2014;63(40):881–5.
39. Sehgal N, Manchikanti L, Smith HS. Prescription Opioid Abuse in Chronic
Pain: A Review of Opioid Abuse Predictors and Strategies to Curb Opioid
Abuse. Pain Physician. 2012;15:ES67–92.
40. Russ AL, Zillich AJ, McManus MS, Doebbeling BN, Saleem JJ. A human
factors investigation of medication alerts: barriers to prescriber decision-
making and clinical workflow. AMIA Annu Symp Proc. 2009;2009:548–52.
41. Kelley J, Kraft-Todd G, Schapira L, Kossowsky J, Riess H. The influence of
the patient-clinician relationship on healthcare outcomes: A systematic
review and meta-analysis of randomized controlled trials. PLoS One.
2014;9(4):e92407.
42. Idemoto L, Wiliams B, Ching J, Blackmore C. Implementation of a custom
alert to prevent medication-timing errors associated with computerized
prescriber order entry. Am J Health Syst Pharm. 2015;72(17):1481–8.
Seymour et al. BMC Medical Informatics and Decision Making  (2016) 16:111 Page 9 of 10
43. Stewart M, Mcwhinney I, Buck C. The doctor/patient relationship and its
effect upon outcome. J R Coll Gen Pract. 1979;29:77–82.
44. Di Blasi Z, Harkness E, Ernst E, Georgiu A, Kleijnen J. Influence of context
effects on health outcomes: A systematic review. Lancet. 2001;357:757–62.
45. Ong L, de Haes J, Hoos A, Lammes F. Doctor-patient communication: A
review of the literature. Soc Sci Med. 1995;40:903–18.
46. Boussadi A, Caruba T, Zapletal E, Sabatier B, Durieux P, Degoulet P. A clinical
data warehouse-based process for refining medication orders alerts. J Am
Med Inform Assoc. 2012;19(5):782–5.
47. Oppenheim M, Mintz R, Boyer A, Frayer W. Design of a clinical alert system
to facilitate development, testing, maintenance, and user-specific
notification. Proc AMIA Symp. 2000;2000:630–4.
48. Russ AL, Chen S, Melton BL, Saleem JJ, Weiner M, Spina JR, et al. Design and
evaluation of an electronic override mechanism for medication alerts to
facilitate communication between prescribers and pharmacists. Ann
Pharmacother. 2015;49(7):761–9.
49. Bonar EE, Ilgen MA, Walton M, Bohnert AS. Associations among pain, non-
medical prescription opioid use, and drug overdose history. Am J Addict.
2014;23(1):41–7. doi:10.1111/j.1521-0391.2013.12055.x.
50. Zedler B, Xie L, Wang L, Joyce A, Vick C, Kariburyo F, et al. Risk Factors for
Serious Prescription Opioid-Related Toxicity or Overdose among Veterans Health
Administration Patients. Pain Med. 2014;15:1911–29. doi:10.1111/pme.12480.
51. Jones C, Paulozzi LJ, Mack KA. Sources of prescription opioid pain relievers
by frequency of past-year nonmedical use: United States, 2008–2011. JAMA
Internal Med. 2014;174(5):802–3. doi:10.1001/jamainternmed.2013.1809.
52. Weiner SG, Griggs CA, Langlois BK, Mitchell PM, Nelson KP, Friedman FD, et
al. Characteristics of emergency department “doctor shoppers”. J Emerg
Med. 2015;48(4):424–31. doi:10.1016/j.jemermed.2014.11.008. e1.
53. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of
abuse among unintentional pharmaceutical overdose fatalities. JAMA.
2008;300(22):2613–20. doi:10.1001/jama.2008.802.
54. Lanier WA, Johnson EM, Rolfs RT, Friedrichs MD, Grey TC. Risk factors
for prescription opioid-related death, Utah, 2008–2009. Pain Med.
2012;13:1580–9. doi:10.1111/j.1526-4637.2012.01518.x.
55. Hasegawa K, Brown DF, Tsugawa Y, Camargo Jr CA. Epidemiology of
emergency department visits for opioid overdose: a population-based
study. Mayo Clin Proc. 2014;89(4):462–71. doi:10.1016/j.mayocp.2013.12.008.
56. Peirce GL, Smith MJ, Abate MA, Halverson J. Doctor and pharmacy
shopping for controlled substances. Med Care. 2012;50:494–500.
doi:10.1097/MLR.0b013e31824ebd81.
57. Stogner JM, Sanders A, Miller BL. Deception for drugs: self-reported “doctor
shopping” among young adults. J Am Board Fam Med. 2014;27(5):583–93.
doi:10.3122/jabfm.2014.05.140107.
58. Silva K, Schrager SM, Kecojevic A, Lankenau SE. Factors associated with history of
non-fatal overdose among young nonmedical users of prescription drugs. Drug
Alcohol Depend. 2013;128(1–2):104–10. doi:10.1016/j.drugalcdep.2012.08.014.
59. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated
patients: Preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):
432–42. doi:10.1111/j.1526-4637.2005.00072.x.
60. Grover CA, Elder JW, Close RJ, Curry SM. How Frequently are “Classic”
Drug-Seeking Behaviors Used by Drug-Seeking Patients in the
Emergency Department? West J Emerg Med. 2012;13(5):416–21.
doi:10.5811/westjem.2012.4.11600.
61. Toblin RL, Paulozzi LJ, Logan JE, Hall AJ, Kaplan JA. Mental illness and
psychotropic drug use among prescription drug overdose deaths:
a medical examiner chart review. J Clin Psychiatry. 2010;71(4):491–6.
doi:10.4088/JCP.09m05567blu.
62. Beaudoin FL, Straube S, Lopez J, Mello MJ, Baird J. Prescription opioid
misuse among ED patients discharged with opioids. Am J Emerg Med.
2014;32(6):580–5. doi:10.1016/j.ajem.2014.02.030.
63. Katz C, El-Gabalawy R, Keyes KM, Martins SS, Sareen J. Risk factors for
incident nonmedical prescription opioid use and abuse and dependence:
results from a longitudinal nationally representative sample. Drug Alcohol
Depend. 2013;132(1–2):107–13. doi:10.1016/j.drugalcdep.2013.01.010.
64. Sundquist J, Ohlsson H, Sundquist K, Kendler KS. Attention-deficit/hyperactivity
disorder and risk for drug use disorder: a population-based follow-up and co-
relative study. Psychol Med. 2015;45(5):977–83. doi:10.1017/S0033291714001986.
65. Morris BJ, Zumsteg JW, Archer KR, Cash B, Mir HR. Narcotic Use and
Postoperative Doctor Shopping in the Orthopaedic Trauma Population.
J Bone Joint Surg Am. 2014;96(15):1257–62. doi:10.2106/JBJS.M.01114.
66. Bohnert ASB, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al.
Association Between Opioid Prescribing Patterns and Opioid Overdose-
Related Deaths. JAMA. 2011;305(13):1315–21. doi:10.1001/jama.2011.370.
67. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD,
et al. Opioid Prescriptions for Chronic Pain and Overdose: A Cohort Study. Ann
Intern Med. 2010;152:85–92. doi:10.7326/0003-4819-152-2-201001190-00006.
68. Zechnick AD, Hedges JR. Community-wide emergency department visits by
patients suspected of drug-seeking behavior. Acad Emerg Med. 1996;3(4):
312–7. doi:10.1111/j.1553-2712.1996.tb03443.x.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Seymour et al. BMC Medical Informatics and Decision Making  (2016) 16:111 Page 10 of 10
